We are live on ! Find out more
XRTX icon

XORTX Therapeutics
XRTX

3 hedge funds and large institutions have $6.25K invested in XORTX Therapeutics in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.09% less ownership

Funds ownership: 3.31% → 0.22% (-3.1%)

50% less funds holding

Funds holding: 6 → 3 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

94% less capital inflows, than outflows

Capital inflows: $7.02K | Capital outflows: $123K

Holders
3
Holders Change
-3
Holders Change %
-50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Kingsview Wealth Management
Kingsview Wealth Management
Oregon
+$7K
2
TD Waterhouse Canada
TD Waterhouse Canada
Ontario, Canada
+$21

Top Sellers

Rank Fund Capital Flow
1
DRW Securities
DRW Securities
Illinois
-$109K
2
Two Sigma Securities
Two Sigma Securities
New York
-$7.08K
3
Baader Bank Aktiengesellschaft
Baader Bank Aktiengesellschaft
Germany
-$4.74K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$2K
5
UBS Group
UBS Group
Switzerland
-$787

XRTX Hedge Fund Activity: Q1 2026 in Review

3 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q1 2026, worth a combined $6.25K — down 95% from $124K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of XRTX and 2 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Kingsview Wealth Management, opening a new position worth an estimated $7K. The largest seller was DRW Securities, exiting entirely with an estimated $109K sold.

  • 3 institutional investors held XORTX Therapeutics (XRTX) as of Q1 2026, down from 6 in Q4 2025.
  • Funds reported $6.25K of XORTX Therapeutics stock for Q1 2026, down 95% quarter-over-quarter.
  • 2 funds opened new XORTX Therapeutics positions in Q1 2026 and 5 closed out, a net change of -3 holders.
  • The largest XORTX Therapeutics buyer in Q1 2026 was Kingsview Wealth Management, an estimated $7K added.
  • The largest XORTX Therapeutics seller in Q1 2026 was DRW Securities, an estimated $109K sold.

Based on aggregated 13F filings for Q1 2026.